Erin K. Crane

Dr. Erin K. Crane

Oncology
1021 Morehead Medical Drive, Suite 2100, 
Charlotte, NC 
On Staff At
Accepting New Patients
Offers Telehealth
1021 Morehead Medical Drive, Suite 2100, 
Charlotte, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Erin Crane is an Oncologist in Charlotte, North Carolina. Dr. Crane is rated as an Experienced provider by MediFind in the treatment of Endometritis. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Bladder Reconstruction, and Endoscopy. Dr. Crane is currently accepting new patients.

Her clinical research consists of co-authoring 37 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
SUNY Upstate Medical University, Syracuse, NY
Residency
University of Virginia, Obstetrics and Gynecology
Specialties
Oncology
Licenses
Obstetrics & Gynecology in NC
Board Certifications
American Board Of Obstetrics And Gynecology, Gynecologic Oncology
Fellowships
The University of Texas MD Anderson Cancer Center, Gynecologic Oncology
Hospital Affiliations
Atrium Health Union
Atrium Health Cleveland
Carolinas Medical Center/behav Health
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Atrium Health Levine Cancer Institute (Gynecologic Cancer)
1021 Morehead Medical Drive, Suite 2100, Charlotte, NC 28204
Other Locations
Atrium Health Levine Cancer Institute
15830 Ballantyne Medical Place, Charlotte, NC 28277

Additional Areas of Focus

Dr. Crane has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Vulvar Cancer
Cervical Cancer
Endometrial Cancer
Cervical Dysplasia
Ovarian Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer
A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Radiation, Drug
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
Minimally Invasive Interval Debulking Surgery in Ovarian Cancer
Minimally Invasive Interval Debulking Surgery in Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 14, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
View 5 Less Clinical Trials

37 Total Publications

Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine.
Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine.
Journal: Future oncology (London, England)
Published: November 05, 2025
Similar Doctors
Experienced in Endometritis
Dr. David L. Tait
Gynecologic Oncology | Oncology
Experienced in Endometritis
Dr. David L. Tait
Gynecologic Oncology | Oncology
1350 S Kings Dr, 
Charlotte, NC 
 (0.7 miles away)
704-446-1544
Languages Spoken:
English
See accepted insurances

David Tait is a Gynecologic Oncologist and an Oncologist in Charlotte, North Carolina. Dr. Tait is rated as a Distinguished provider by MediFind in the treatment of Endometritis. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Ureteral Reconstruction, and Bladder Reconstruction.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Crane's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile